Navigation Links
International ENDORSE Study Shows That the Majority of Hospitalized,Patients Surveyed are at Risk for VTE and Many do not Receive,Recommended VTE prophylaxis

efinition of patients at risk of VTE and prophylaxis recommendations provided by the of Chest Physicians (ACCP) evidence-based consensus guidelines (3). The study included two categories of hospitalized patients: patients in medical wards 40 years of age or older, and patients in surgical wards, 18 years or older.

Doctor Fred Anderson, Director of the Center for Outcomes Research at the University of Massachusetts Medical School who conducted the study commented "ENDORSE is the first study to provide a global view of VTE risk and prophylaxis practices throughout the world. With more than 60,000 patients studied in more than 30 countries, the scope of ENDORSE is unprecedented. In view of the quality of the data collected and a common method to assess patients at risk for VTE and prophylaxis used, this study gives us a unique picture both globally and locally about the extent of the hospitalized patient population at risk for VTE and how these patients are managed."

ENDORSE demonstrates the high prevalence of patients at risk for VTE: 52% of hospitalized patients surveyed were at risk for VTE, corresponding to 64% of surgical patients and 42% of medical patients. The prevalence of patients at risk was consistent across the countries surveyed, demonstrating the importance of VTE risk on a global scale.

Importantly, when considering the use of recommended prophylaxis in hospitals, only 50% of hospitalized patients at risk for VTE received a method of prophylaxis recommended by the ACCP, corresponding to 59% of surgical and 40% of medical patients at risk for VTE. The use of recommended prophylaxis varied across countries; however, it was globally sub-optimal and even more so in medical than surgical patients, as the majority of medical patients at risk for VTE (60%) did not receive recommended prophylaxis.

As highlighted by Doctor Victor Tapson, Co-chair of the ENDORSE Steering Committee: "ENDORSE clearly shows that VTE is a critical safety i
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
6. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
8. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
11. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
Post Your Comments:
(Date:8/29/2014)... Aug. 29, 2014  Unilife Corporation ("Unilife" or "Company") ... that it intends to release its financial results for ... 30, 2014 after market trading ends on Tuesday, September ... conference call for 4:30 p.m. U.S. EDT on Tuesday, ... a.m. AEST), to review the Company,s financial results, commercial partnerships, ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... Multiple Sclerosis Drugs Market 2014-2018" report to their ... inflammatory medical condition that results in demyelination, axonal transection, ... an abnormal response by the immune system, which targets ... a potentially debilitating disease in which the damage of ...
(Date:8/29/2014)... UNION CITY, Calif. , Aug. 29, 2014 /PRNewswire/ ... products company manufacturing point-of-care blood instrumentation and consumables to ... Clint Severson , Chairman and Chief Executive Officer, ... Annual Best Ideas Conference 2014 on Tuesday, September 9, ... held at the Omni Berkshire Place Hotel in ...
Breaking Medicine Technology:Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2
... Novavax, Inc. (Nasdaq: NVAX ) announced today ... its virus-like-particle (VLP) H1N1 influenza vaccine in Mexico in ... Avimex distributes biological and pharmaceutical products for use in ... world. Avimex is providing financial support for the ...
... , SHENYANG, China, Oct. 20 ... "Company"), a leading China-based biotechnology,company focused on researching, developing, ... its annual general,meeting of shareholders held on October 12, ... the Company,s shareholders re-elected Dr. Jing Lou and Mr.,Moujia ...
Cached Medicine Technology:Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico 2Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico 3Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico 4Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico 5
(Date:8/30/2014)... Patients suffering from vitiligo can now ... new review published by Daily Gossip. , Vitiligo ... there is no wonder that numerous sufferers search for ... Treatment is one of the most appreciated such methods ... to stop the spread of this disorder immediately, while ...
(Date:8/30/2014)... Daily Gossip magazine reveals in its ... panic attacks under control with a simple and efficient ... describes this new method as an anxiety recovery program ... overcome general anxiety related disorders. , What makes ... that it can be accessed by users from the ...
(Date:8/30/2014)... NJ (PRWEB) August 30, 2014 The ... facilities in New Jersey and even in the U.S. ... that takes inches off of patients’ waists with deep-tissue ... cells in small sections, Vanquish is more inclusive to ... Patients lay comfortably under panels about one inch ...
(Date:8/30/2014)... 2014 RB SEO Services, a well-recognized ... for small businesses. , RBSEO Services knows this very ... search engine optimization service. So, the company has introduced ... account. , On being asked about the service, ... low cost SEO service because many small businesses expressed ...
(Date:8/30/2014)... NY (PRWEB) August 30, 2014 ... throughout the planet has been one of the ... order to create a positive impact around the ... and staffed with top trained executives and trainers ... of people worldwide. Vital statistics demonstrate that ...
Breaking Medicine News(10 mins):Health News:Natural Vitiligo Treatment Review Exposes Fast Method for Skin Repigmentation 2Health News:Panic Away Review Reveals New Natural Remedy for Anxiety Patients 2Health News:NJ Top Docs Presents, The Plastic Surgery Group 2Health News:RBSEO Services Introduces Low Cost SEO Service for Small Businesses 2Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2
... , , , FOSTER ... WHAT: Siperian, Inc., a leading industry provider of a multidomain master ... IBM Global Business Services and Boehringer Ingelheim have teamed up for an ... Most Valuable?" Hussain Mooraj, vice president, Healthcare ...
... HONG KONG, Sept. 16 /PRNewswire-Asia/ -- At ... September 10, reporters were informed that the,First World Conference ... Physicians) and the First World Endoscopy Technology Expo,will be ... Professor Zhang Yangde, the chief ...
... HBV genotypes as well as mutations in the core promoter, ... association with the clinical outcome of liver disease, however, this ... the HBV genotype distribution in certain region. So far, there ... country with a big population and a relatively high HBV ...
... , , MENLO PARK, ... label-free technology that accelerates the development of biotherapeutic and pharmaceutical ... and Read Immunogenicity Assay Kit for rapid detection of anti-drug ... new assay kit provides life science researchers with new levels ...
... , , , NEW YORK, ... has received Orphan-Drug designation from the U.S. Food and Drug Administration ... announced that it had reached an agreement with the FDA regarding ... 3 trial in relapsed/refractory multiple myeloma and that the study is ...
... study finds supervised exercise has better results , WEDNESDAY, ... than shockwave treatment for relieving chronic shoulder pain, according ... used to treat shoulder pain, even though a number ... investigate, Norwegian researchers studied 104 men and women, aged ...
Cached Medicine News:Health News:Siperian to Host Webinar With Panel of Pharmaceutical Experts 2Health News:Siperian to Host Webinar With Panel of Pharmaceutical Experts 3Health News:Siperian to Host Webinar With Panel of Pharmaceutical Experts 4Health News:Siperian to Host Webinar With Panel of Pharmaceutical Experts 5Health News:The First World Conference of Endoscopy Physicians will be Held December 18-20, 2009, in Hong Kong 2Health News:The First World Conference of Endoscopy Physicians will be Held December 18-20, 2009, in Hong Kong 3Health News:ForteBio Launches Dip and Read(TM) Immunogenicity Assay Kit for Rapid Detection of Anti-Drug Antibodies 2Health News:Keryx Biopharmaceuticals Receives Orphan-Drug Designation for KRX-0401 (Perifosine) for the Treatment of Multiple Myeloma 2Health News:Keryx Biopharmaceuticals Receives Orphan-Drug Designation for KRX-0401 (Perifosine) for the Treatment of Multiple Myeloma 3Health News:Keryx Biopharmaceuticals Receives Orphan-Drug Designation for KRX-0401 (Perifosine) for the Treatment of Multiple Myeloma 4Health News:Shockwave Treatment May Not Be Best for Shoulder Pain 2
Stainless steel tray for sterilizing instruments....
For sterilizing, carrying and storage of a Storz diamond knife and barrel gauge....
Diamond knife tray with silicone inserts to securely hold the diamond knife....
Diamond knife tray with silicone inserts to securely hold the diamond knife....
Medicine Products: